Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin inhibitor Camzyos (mavacamten) in China. The drug is indicated for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) graded II to III under the New York Heart Association (NYHA) functional classification, aiming to improve exercise capacity and symptoms.
Camzyos exerts its action on cardiac myosin, mitigating the formation of excessive myosin and actin bridges. This mechanism alleviates excessive myocardial contraction, enhances diastolic function, and significantly improves the left ventricular outflow tract (LVOT) pressure gradient and NYHA heart function grading. Studies have demonstrated the drug’s ability to notably improve patients’ exercise ability and overall quality of life.
Camzyos received its inaugural approval in the U.S. in April 2022 for the treatment of class II-III obstructive HCM (oHCM). Since then, it has gained approvals in significant markets, including South Korea, Macau, and Singapore across Asia. The Hainan Bo’ao Medical Pilot Zone initiated the use of the drug in January this year, marking a significant step towards broadening patient access in the region.- Flcube.com
